Last updated: March 4, 2026
What Are the Case Details?
Cephalon Inc. filed suit against Watson Laboratories Inc. in the United States District Court for the District of Delaware. The case number is 1:10-cv-00007, initiated in 2010.
-
Nature of dispute: Patent infringement claim regarding patents related to CEPhalon’s branded drug Provigil (modafinil).
-
Key Patent: Patent No. 7,346,415, granted in March 2008, covering methods of using modafinil for the treatment of sleep disorders and other indications.
-
Defendant's product: Watson Laboratories developed a generic version of Provigil, seeking FDA approval to market a bioequivalent drug.
-
Timeline:
- Watson filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification in early 2010.
- Cephalon responded with patent infringement litigation within the statutory 45-day period mandated by the Hatch-Waxman Act.
Litigation Progress
-
2010: Watson filed ANDA seeking approval for generic modafinil. Cephalon responded with patent infringement suit under the Hatch-Waxman Act, triggering an automatic stay of FDA approval.
-
2011-2013: The case underwent pretrial motions, including disputes over patent validity, infringement, and the scope of claims.
-
Summary Judgment: Several motions filed by both parties; Cephalon sought to exclude certain defenses, while Watson challenged patent validity based on obviousness and prior art references.
-
Trial date: Scheduled for late 2012 but delayed multiple times due to motions and settlement discussions.
Settlement and Resolution
-
2013: The parties reached a settlement agreement, resulting in Watson receiving a license under Cephalon’s patents and ceasing patent infringement litigation.
-
Impact: Watson was permitted to market its generic product beginning July 2012, nine months before the patent's expiration date, under a patent license settlement.
Key Legal Issues
Patent Validity
- Watson challenged patent claims for obviousness, citing prior art references.
- Cephalon defended claims based on unexpected results and commercial success.
Patent Infringement
- Watson’s generic was accused of infringing specific claims related to the method of use of modafinil.
Hatch-Waxman Act
- The case involved the litigation process triggered by ANDA and Paragraph IV certification.
- The automatic stay of FDA approval and potential for patent damages were central to the case.
Legal Outcomes
- The case was settled before a final court ruling was issued.
- The settlement included licensing terms that allowed Watson to market a generic version, avoiding a lengthy patent trial or invalidation.
Trends and Implications
- The case underscores the importance for patent holders to defend method-of-use patents within the Hatch-Waxman framework.
- It reflects how patent settlements can expedite generic entry while providing patent holders with licensing revenue.
- Highlights the strategic use of patent challenges to extend market exclusivity indirectly.
Competitive & Market Impact
- The settlement allowed Watson to enter the market early, gaining market share for modafinil.
- Cephalon maintained patent rights for other indications, prolonging commercial exclusivity for its branded product.
Key Takeaways
- Cephalon v. Watson exemplifies the intricate legal maneuvering under Hatch-Waxman, including patent validity, infringement, and settlement strategies.
- Patent litigations linked to ANDA filings significantly influence generic drug timelines and market dynamics.
- Settlement agreements often resolve patent disputes before definitive court rulings, impacting patent life and market competition.
- The case demonstrates that challenging method-of-use patents remains a viable strategy for generic entrants.
FAQs
1. How does the Hatch-Waxman Act influence patent litigation like Cephalon v. Watson?
It triggers an automatic stay of FDA approval upon filing a Paragraph IV certification, leading to patent infringement lawsuits and setting the stage for settlement or trial.
2. What is the significance of patent claims regarding method of use?
Method-of-use patents can extend drug exclusivity despite generic entry, though they are often more vulnerable to validity challenges.
3. How do settlements shape the generic drug market?
They can lead to early market entry through licensing agreements, bypassing lengthy patent challenges.
4. What are common defenses in patent infringement cases involving generics?
Obviousness, lack of novelty, patent invalidity, and non-infringement are key defenses used by generics.
5. How do patent challenges in FDA regulatory pathways impact innovation?
They can delay generic entry but also promote patent quality and strategic patenting practices.
References
- U.S. District Court for the District of Delaware. (2010). Cephalon Inc. v. Watson Laboratories Inc., Case No. 1:10-cv-00007.
- Hatch-Waxman Act, 21 U.S.C. §§ 355 and 355(j).
- U.S. Patent No. 7,346,415.
- Federal Trade Commission. (2014). Settlement trends in patent litigation involving generic drugs.
